BioCentury
ARTICLE | Company News

Vernalis, AstraZeneca deal

October 20, 2003 7:00 AM UTC

AZN will use VER's structure-based drug discovery (SBDD) technology to study AZN compounds against anti-infective targets. SBDD was developed by RiboTargets Ltd., which was acquired by British Biotec...